Inebilizumab for children with generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests if an investigational drug called inebilizumab is safe and helpful for children with generalized myasthenia gravis (gMG). It is for children ages 2 to 17 who have certain antibodies or typical symptoms of gMG and are already on stable treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 17 years old.
- You need a confirmed diagnosis of generalized myasthenia gravis with a positive antibody test (AChR or MuSK) and symptoms that match gMG.
- Your MG classification should be class II, III, or IV (moderate to severe symptoms).
- You must be on a stable dose of corticosteroids or other allowed immunosuppressants (like azathioprine or mycophenolate) for a certain time before starting.
- You cannot have taken certain medications that deplete B-cells (like rituximab) or other monoclonal antibodies in the last 6 months.
- You cannot have active infections like HIV, hepatitis B or C, tuberculosis, or a history of progressive multifocal leukoencephalopathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
This study tests a new daily shot (zilucoplan) for children and teens with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It aims to see if the drug is safe and helps improve strength and daily functioning.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.